Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 300,492,096
  • Shares Outstanding, K 2,532,806
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.39
  • Price/Sales 4.98
  • Price/Cash Flow 38.78
  • Price/Book 6.84
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 18.03% ( -0.49%)
  • Historical Volatility 14.15%
  • IV Percentile 31%
  • IV Rank 23.95%
  • IV High 27.33% on 07/26/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 1.38
  • Today's Volume 23,548
  • Volume Avg (30-Day) 25,755
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 404,434
  • Open Int (30-Day) 392,735

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.77
  • Number of Estimates 8
  • High Estimate 2.11
  • Low Estimate 1.54
  • Prior Year 2.13
  • Growth Rate Est. (year over year) -16.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.41 +6.23%
on 09/09/24
120.30 -0.74%
on 09/06/24
+4.99 (+4.36%)
since 08/19/24
3-Month
110.72 +7.85%
on 08/07/24
134.63 -11.31%
on 06/25/24
-8.58 (-6.70%)
since 06/18/24
52-Week
99.14 +20.45%
on 10/19/23
134.63 -11.31%
on 06/25/24
+12.05 (+11.22%)
since 09/19/23

Most Recent Stories

More News
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 79.21 (+0.80%)
PFE : 29.85 (+0.34%)
MRK : 119.41 (+0.65%)
LLY : 913.98 (+1.00%)
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

MRK : 119.41 (+0.65%)
SMMT : 25.15 (+2.40%)
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 119.41 (+0.65%)
PFE : 29.85 (+0.34%)
MRNA : 71.30 (+2.06%)
VRTX : 474.16 (-1.48%)
VKTX : 65.99 (+2.39%)
Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?

Summit Therapeutics is a clinical-stage biotech company that has returned over 1,100% in 2024. Is the stock still a good buy right now?

SMMT : 25.15 (+2.40%)
MRK : 119.41 (+0.65%)
C : 60.93 (+1.72%)
Where Will Merck Stock Be in 5 Years?

This drugmaker faces a key test in the next several years.

MRK : 119.41 (+0.65%)
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...

SNY : 57.74 (+0.47%)
GSK : 42.54 (+0.26%)
MRK : 119.41 (+0.65%)
MRNA : 71.30 (+2.06%)
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

MRK : 119.41 (+0.65%)
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been...

BMY : 49.83 (+0.18%)
PFE : 29.85 (+0.34%)
MRK : 119.41 (+0.65%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 119.41 (+0.65%)
NVS : 116.32 (+0.30%)
KTRA : 0.1722 (-1.60%)
RKV.VN : 0.085 (-5.56%)
RHHBY : 39.6100 (+0.71%)
XBIT : 7.50 (+1.49%)
BMRN : 71.50 (+0.51%)
AZN : 79.21 (+0.80%)
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

Merck’s MRK stock declined 2% on Monday after Summit Therapeutics’ SMMT investigational bispecific antibody, ivonescimab, outperformed Merck’s blockbuster PD-L1 inhibitor Keytruda in a first-line...

RHHBY : 39.6100 (+0.71%)
MRK : 119.41 (+0.65%)
LLY : 913.98 (+1.00%)
SMMT : 25.15 (+2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 120.90
2nd Resistance Point 120.14
1st Resistance Point 119.39
Last Price 119.41
1st Support Level 117.88
2nd Support Level 117.12
3rd Support Level 116.37

See More

52-Week High 134.63
Fibonacci 61.8% 121.07
Last Price 119.41
Fibonacci 50% 116.89
Fibonacci 38.2% 112.70
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar